Search results for "Color"

showing 10 items of 2721 documents

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

2021

POLE, POLD1, and NTHL1 are involved in DNA replication and have recently been recognized as hereditary cancer-predisposing genes, because their alterations are associated with colorectal cancer and other tumors. POLE/POLD1-associated syndrome shows an autosomal dominant inheritance, whereas NTHL1-associated syndrome follows an autosomal recessive pattern. Although the prevalence of germline monoallelic POLE/POLD1 and biallelic NTHL1 pathogenic variants is low, they determine different phenotypes with a broad tumor spectrum overlapping that of other hereditary conditions like Lynch Syndrome or Familial Adenomatous Polyposis. Endometrial and breast cancers, and probably ovarian and brain tumo…

MaleCancer ResearchSettore MED/06 - Oncologia MedicaColorectal cancerBiologymedicine.disease_causeGermlineFamilial adenomatous polyposisDeoxyribonuclease (Pyrimidine Dimer)Breast cancerNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseasePoly-ADP-Ribose Binding ProteinsMolecular BiologyDNA Polymerase IIIGenetic testingMutationPOLD1medicine.diagnostic_testDNA Polymerase IIDNAmedicine.diseaseLynch syndromePOLE POLD1 and NTHL1Lynch SyndromeCancer researchFemaleOncogene
researchProduct

Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of th…

2021

Abstract Background Current knowledge about the promotion of long-term physical activity (PA) maintenance in cancer survivors is limited. The aims of this study were to 1) determine the effect of self-regulatory BCTs on long-term PA maintenance, and 2) identify predictors of long-term PA maintenance in cancer survivors 12 months after participating in a six-month exercise intervention during cancer treatment. Methods In a multicentre study with a 2 × 2 factorial design, the Phys-Can RCT, 577 participants with curable breast, colorectal or prostate cancer and starting their cancer treatment, were randomized to high intensity exercise with or without self-regulatory behaviour change technique…

MaleCancer ResearchTime FactorsCancer survivorsLogistic regressionBody Mass Indexlaw.inventionTobacco UseProstate cancerRandomized controlled trialBehavior TherapylawOdds RatioMedicineRC254-282DeterminantsHigh intensityNeoplasms. Tumors. Oncology. Including cancer and carcinogensBehaviour changeMiddle AgedBehavioural supportEndurance TrainingVDP::Medisinske Fag: 700::Helsefag: 800OncologySelf-regulationRegression AnalysisFemaleColorectal NeoplasmsMonth follow upmedicine.medical_specialtyBehaviour changeMaintenancePhysical activityBreast NeoplasmsSelf-ControlConfidence IntervalsGeneticsHumansExerciseSwedenMotivationCancer och onkologibusiness.industryResearchProstatic NeoplasmsCancerResistance Trainingmedicine.diseaseActigraphyCancer and OncologyQuality of LifePhysical therapybusinessFollow-Up StudiesBMC Cancer
researchProduct

Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.

2016

Purpose To evaluate the influence of radiation dose on tumor regression grade (TRG) and sphincter preservation rate in a series of cT3N0-1 rectal cancer patients treated with neoadjuvant chemoradiotherapy (CT-RT) with or without a sequential radiation boost. Materials and methods Between May 2002 and September 2013, 116 cases were eligible for retrospective evaluation. Radiotherapy was delivered for a total dose of 45 Gy (no boost arm) or 50.4 Gy (boost arm). TRG was evaluated with the Dworak scale. Results Median follow-up was 62 months (range, 12-138 months). The 5-year overall survival and local control rates were 72% and 93%, respectively. Fifty-five patients (47%) were treated with a s…

MaleCancer ResearchTime FactorsTumor downsizingColorectal cancermedicine.medical_treatmentAnal CanalKaplan-Meier EstimateSingle Center030218 nuclear medicine & medical imaging0302 clinical medicineAdjuvantNeoadjuvant therapyDigestive System Surgical ProceduresTumor Regression GradeIleostomyMedicine (all)Colorectal cancer; Radiation therapy; Tumor downsizing; Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileostomy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Adjuvant; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle AgedNeoadjuvant TherapyRadiation therapyTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologyFluorouracilmedicine.drugAdultmedicine.medical_specialtyUrogenital SystemAntineoplastic AgentsAdenocarcinomaCapecitabine03 medical and health sciencesmedicineHumansCapecitabineAgedNeoplasm StagingRetrospective StudiesRadiotherapybusiness.industryRectal Neoplasmsmedicine.diseaseColorectal cancerRadiation therapyGastrointestinal TractConcomitantRadiotherapy AdjuvantbusinessOrgan Sparing TreatmentsChemoradiotherapyFollow-Up StudiesTumori
researchProduct

Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer.

2005

The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription…

MaleCancer ResearchTranscription Geneticmedicine.disease_causeCell MovementNeoplasmsGene expressionDrosophila ProteinsIntestinal MucosaCytoskeletonReverse Transcriptase Polymerase Chain ReactionCell CycleCell migrationCell DifferentiationMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticDrosophila melanogasterDisease ProgressionFemaleColorectal NeoplasmsAdenomaAdultTumor suppressor geneBlotting WesternGreen Fluorescent ProteinsDown-RegulationBiologyCell LineDownregulation and upregulationCell Line TumorGeneticsmedicineCell AdhesionAnimalsHumansCell adhesionMolecular BiologyGeneTumor Suppressor ProteinsCarcinomaProteinsProtein Structure TertiaryCytoskeletal ProteinsMicroscopy FluorescenceTumor progressionImmunologyCancer researchCaco-2 CellsCarcinogenesisOncogene
researchProduct

Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer

2008

Background: A variety of molecular markers have been evaluated for the development of a non-invasive approach to the diagnosis of colorectal cancer. We aimed to validate the diagnostic accuracy, using the same threshold as in the previous pilot study, of fluorescent long DNA test as a relatively simple and inexpensive tool for colorectal cancer detection.Methods: A case-control study was conducted on 100 healthy subjects and 100 patients at first diagnosis of colorectal cancer. Human long-fragment DNA in stool was quantified by fluorescence primers and a standard curve and expressed in DNA nanograms.Results: We validated the 25-ng value, which emerged as the most accurate cut-off in the pil…

MaleCancer ResearchdiagnosisAdenomatous Polyposis Coli Proteinlong-fragment DNAcolorectal cancercolorectal cancerlcsh:RC254-282Polymerase Chain ReactionPathology and Forensic MedicineFecesFluorescence long DNABiomarkers TumorHumanslcsh:QH573-671stoolEarly Detection of CancerAgedDNA PrimersFluorescent DyesAged 80 and overlcsh:CytologyCell BiologyGeneral MedicineDNAMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCase-Control StudiesMolecular MedicineFemaleOtherTumor Suppressor Protein p53Colorectal Neoplasms
researchProduct

Familial aggregation of tumors and detection of hereditary non-polyposis colorectal cancer in 3-year experience of 2 population-based colorectal-canc…

1995

The clinical data of 2 population-based registries, located in areas with different incidence rates of colorectal cancer, were used in order to assess the role of familial factors in the pathogenesis of these tumors. The occurrence of tumors in family members was investigated in 389 subjects with colorectal cancer registered in Modena (Northern Italy, an area characterized by a high incidence of colorectal malignancies) between 1984 and 1986; similar information was obtained in 213 patients with tumors of the large bowel registered in Ragusa (Sicily, Southern Italy, an area of similar magnitude and with low incidence rates for these tumors) in the 3-year period 1988 to 1990. In both series,…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPopulationRisk FactorsInternal medicineEpidemiologyPrevalenceMedicineHumansRegistriesRisk factoreducationAgedFamily Healtheducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceCancerFamily aggregationmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisLynch syndromeSurgerynot availableOncologyItalyEvaluation Studies as TopicCase-Control StudiesFemalebusinessColorectal NeoplasmsInternational journal of cancer
researchProduct

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

2019

To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, a…

MaleCancer Researchmedicine.medical_specialtyColorectal cancerPrevalenceSocio-culturaleColonoscopyColorectal NeoplasmSettore MED/42 - Igiene Generale E Applicatacolorectal cancer screeningScreening programmeFeces03 medical and health sciences0302 clinical medicinecolonoscopyFaecal immunochemical test colonoscopy colorectal cancer screening epidemiology cancer registriesInternal medicineEpidemiologymedicineHumansStage (cooking)Early Detection of CancerAgedNeoplasm StagingProportional Hazards Modelscancer registriemedicine.diagnostic_testFaecal immunochemical testbusiness.industryIncidence (epidemiology)IncidenceMiddle Agedmedicine.diseaseImmunohistochemistryOncologyItalycancer registries030220 oncology & carcinogenesisRelative riskOccult BloodepidemiologyFeceFemaleNeoplasm GradingColorectal NeoplasmsbusinessHuman
researchProduct

Colorectal cancer stage at diagnosis in migrants versus non-migrants (KoMigra) : study protocol of a cross-sectional study in Germany

2014

Background: In Germany, about 20% of the total population have a migration background. Differences exist between migrants and non-migrants in terms of health care access and utilisation. Colorectal cancer is the second most common malignant tumour in Germany, and incidence, staging and survival chances depend, amongst other things, on ethnicity and lifestyle. The current study investigates whether stage at diagnosis differs between migrants and non-migrants with colorectal cancer in an area of high migration and attempts to identify factors that can explain any differences. Methods/Design: Data on tumour and migration status will be collected for 1,200 consecutive patients that have receive…

MaleCancer Researchmedicine.medical_specialtyCross-sectional studyLogistic regressionMigrantsHealth Services AccessibilityStudy ProtocolCross-sectionalGermanySurveys and QuestionnairesObservational studyHealth careEthnicityGeneticsHumansMedicineProspective Studiesddc:610Hard-to-reach populationProspective cohort studySocioeconomic statusAgedNeoplasm StagingTransients and MigrantsGynecologybusiness.industryOdds ratioMiddle AgedColorectal cancerCross-Sectional StudiesOncologyHealth care accessHard-to-reach population ; Ethnicity ; Observational study ; Migrants ; Colorectal cancer ; Health care access ; Cross-sectionalFemaleObservational studyOrdered logitColorectal NeoplasmsbusinessDemography
researchProduct

Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

2003

Outcome of patients with metastatic disease mainly depends on accurate preoperative tumor staging. 18[F]fluorodeoxyglucose positron emission tomography (18F-PET) has been proven to be a valuable diagnostic tool in a number of different tumors but its direct influence on liver surgery has not been thoroughly investigated. Between July 1999 and March 2000, 50 consecutive patients with 174 suspected liver lesions were admitted to the University Hospital Jena. All 50 patients underwent abdominal ultrasound, CT-scan, and 18-FDG positron emission tomography scanning. In 23 patients the diagnostic work-up was completed by MRI scan. Altogether there were a total of 174 histologically proven intrahe…

MaleCancer Researchmedicine.medical_specialtyFluorine RadioisotopesLiver tumorCarcinoma HepatocellularBreast NeoplasmsSensitivity and SpecificityResectionAdenoma Liver CellFluorodeoxyglucose positron emission tomographyFluorodeoxyglucose F18Internal medicinemedicineHumansMri scanNeoplasm StagingHematologymedicine.diagnostic_testbusiness.industryUltrasoundLiver NeoplasmsGeneral Medicinemedicine.diseaseUniversity hospitalOncologyPositron emission tomographyFemaleRadiologyRadiopharmaceuticalsbusinessNuclear medicineColorectal NeoplasmsFollow-Up StudiesTomography Emission-ComputedJournal of cancer research and clinical oncology
researchProduct